Disitertide (TFA)

Disitertide (P144) TFA is a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor specifically designed to block the interaction with its receptor. Disitertide TFA is also a PI3K inhibitor and an apoptosis inducer[1][2][3][4][5].

Product Specifications

Product Name Alternative

P144 (TFA)

UNSPSC

12352209

Target

Apoptosis; PI3K; TGF-beta/Smad

Type

Peptides

Related Pathways

Apoptosis; PI3K/Akt/mTOR; Stem Cell/Wnt; TGF-beta/Smad

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/disitertide-tfa.html

Solubility

H2O : < 0.1 mg/mL

Smiles

O=C(O)C(F)(F)F.C[C@@H](O)[C@H](N)C(N[C@@H](CO)C(N[C@@H](CC(C)C)C(N[C@@H](CC(O)=O)C(N[C@@H](C)C(N[C@@H](CO)C(N[C@@H]([C@@H](C)CC)C(N[C@@H]([C@@H](C)CC)C(N[C@H](C(N[C@@H](C)C(N[C@@H](CCSC)C(N[C@@H](CCSC)C(N[C@@H](CCC(N)=O)C(N[C@H](C(O)=O)CC(N)=O)=O)=O)=O)=O)=O)CC1=CNC2=CC=CC=C12)=O)=O)=O)=O)=O)=O)=O)=O

Molecular Formula

C68H109N17O22S2.xC2HF3O2

Molecular Weight

1580.82 (free acid)

References & Citations

[1]Cindy Neuzillet, et al. Targeting the TGFβ pathway for cancer therapy. Pharmacol Ther. 2015 Mar;147:22-31.|[2]Jun Yang, et al. Upregulation of microRNA‑590 in rheumatoid arthritis promotes apoptosis of bone cells through transforming growth factor‑β1/phosphoinositide 3‑kinase/Akt signaling. Int J Mol Med. 2019 May;43 (5) :2212-2220.|[3]Wanming He, et al. MSC-regulated lncRNA MACC1-AS1 promotes stemness and chemoresistance through fatty acid oxidation in gastric cancer. Oncogene. 2019 Jun;38 (23) :4637-4654.|[4]Shan Shan Qiu, et al. Effect of P144® (Anti-TGF-β) in an "In Vivo" Human Hypertrophic Scar Model in Nude Mice. PLoS One. 2015 Dec 31;10 (12) :e0144489.|[5]Gabriel Gallo-Oller, et al. P144, a Transforming Growth Factor beta inhibitor peptide, generates antitumoral effects and modifies SMAD7 and SKI levels in human glioblastoma cell lines. Cancer Lett. 2016 Oct 10;381 (1) :67-75.